Novo Nordisk Cuts Ozempic, Wegovy Prices in India
Analysis based on 8 articles · First reported Mar 30, 2026 · Last updated Mar 31, 2026
The price cuts by Novo Nordisk for Ozempic and Wegovy in India, driven by the expiry of semaglutide's patent and the entry of cheaper generics from companies like Abbott Laboratories and Sun Pharma, will likely lead to increased competition and potentially lower revenues for Novo Nordisk in the Indian market. However, it will also broaden access to these treatments for a larger patient population in India, which could stimulate overall market growth for GLP-1s.
Novo Nordisk has significantly reduced the prices of its diabetes and obesity drugs, Ozempic and Wegovy, in India. This move comes after the patent for semaglutide, the active ingredient, expired on March 20, 2026, leading to a surge of generic versions from Indian pharmaceutical companies such as Natco Pharma, Abbott Laboratories, Glenmark Pharmaceuticals, Sun Pharma, and Torrent Pharmaceuticals. The starting doses of Ozempic and Wegovy will see price reductions of 36% and 48% respectively, effective April 1, 2026. This is Novo Nordisk's second price cut for Wegovy in India, aiming to defend its market share against generics that are priced 50-80% lower. The company emphasizes making cardiometabolic care more affordable in India, a key growth market with a large population of type 2 diabetes and obesity patients. The increased competition is expected to make these therapies more accessible to patients.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard